Literature DB >> 19127544

Diversity of participants in clinical trials in an academic medical center: the role of the 'Good Study Patient?'.

Galen Joseph1, Daniel Dohan.   

Abstract

BACKGROUND: Only 2.5% of adults and even fewer minorities participate in cancer therapeutic trials. Researchers have concluded that many barriers to participation stem from how recruitment is performed by clinician investigators. The objective of the current research was to document specifically how these barriers impede recruitment in the clinical setting.
METHODS: The authors conducted a case study of recruitment in an academic medical center using ethnographic research methods (direct observation of provider-patient interactions and in-depth interviews with providers) to collect data. Qualitative data analysis was used to identify themes related to the provider's role in the recruitment processes.
RESULTS: In the clinics that were studied, the authors observed that providers subjectively assessed which patients seemed to be 'good study patients' to target for recruitment. 'Good study patients' were identified as those who were able to adhere to complex trial protocols, thus helping clinician researchers to complete studies in a timely and efficient manner. These patients were perceived as meticulous, proactive, and compliant; they were considered good communicators; and they were embedded in the kinds of strong social support networks that facilitated their trials participation.
CONCLUSIONS: The providers that were studied sought 'good study patients' for therapeutic trials because they wanted to perform studies in a timely and efficient manner. Future research should examine whether providers in other settings also target their recruitment efforts for this or other reasons. Further research also should consider whether differentially recruiting 'good patients' can impact the ethnic/racial diversity or other characteristics of trial participants in ways that may bias the outcomes or conclusions of therapeutic trials. (c) 2008 American Cancer Society.

Entities:  

Mesh:

Year:  2009        PMID: 19127544     DOI: 10.1002/cncr.24028

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  31 in total

1.  Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm.

Authors:  Roland B Walter; Frederick R Appelbaum; Martin S Tallman; Noel S Weiss; Richard A Larson; Elihu H Estey
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  "The promise of community-based advocacy and education efforts for increasing cancer clinical trials accrual".

Authors:  Margo Michaels; Elisa S Weiss; John A Guidry; Natasha Blakeney; Liz Swords; Brian Gibbs; Samantha Yeun; Bruce Rytkonen; Robert Goodman; S Lisbeth Jarama; Amanda L Greene; Shilpa Patel
Journal:  J Cancer Educ       Date:  2012-03       Impact factor: 2.037

3.  Power of an effective clinical conversation: improving accrual onto clinical trials.

Authors:  Linda K Parreco; Rhonda W DeJoice; Holly A Massett; Rose Mary Padberg; Sona S Thakkar
Journal:  J Oncol Pract       Date:  2012-03-27       Impact factor: 3.840

4.  Five principles for effective cancer clinical trial education within the community setting.

Authors:  Margo Michaels; Natasha Blakeney; Aisha T Langford; Marvella E Ford
Journal:  J Cancer Educ       Date:  2015-03       Impact factor: 2.037

5.  What advanced cancer patients with limited treatment options know about clinical research: a qualitative study.

Authors:  Sarah B Garrett; Christopher J Koenig; Laura Trupin; Fay J Hlubocky; Christopher K Daugherty; Anne Reinert; Pamela Munster; Daniel Dohan
Journal:  Support Care Cancer       Date:  2017-05-09       Impact factor: 3.603

6.  Barriers to Clinical Trial Enrollment in Racial and Ethnic Minority Patients With Cancer.

Authors:  Lauren M Hamel; Louis A Penner; Terrance L Albrecht; Elisabeth Heath; Clement K Gwede; Susan Eggly
Journal:  Cancer Control       Date:  2016-10       Impact factor: 3.302

7.  Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment.

Authors:  Lynne Penberthy; Richard Brown; Maureen Wilson-Genderson; Bassam Dahman; Gordon Ginder; Laura A Siminoff
Journal:  Clin Trials       Date:  2012-10-02       Impact factor: 2.486

8.  Social support, flexible resources, and health care navigation.

Authors:  Elizabeth A Gage-Bouchard
Journal:  Soc Sci Med       Date:  2017-08-18       Impact factor: 4.634

9.  Reaching Hard to Reach Populations with Hard to Communicate Messages: Efficacy of a Breast Health Research Champion Training Program.

Authors:  Carlin Rafie; Antoinette Ayers; Debbie Cadet; John Quillin; Mary H Hackney
Journal:  J Cancer Educ       Date:  2015-09       Impact factor: 2.037

10.  Patient Navigation As a Model to Increase Participation of African Americans in Cancer Clinical Trials.

Authors:  Mona N Fouad; Aras Acemgil; Sejong Bae; Andres Forero; Nedra Lisovicz; Michelle Y Martin; Gabriela R Oates; Edward E Partridge; Selwyn M Vickers
Journal:  J Oncol Pract       Date:  2016-05-17       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.